Objective: To conduct a randomized prospective trial of immune globulin treatment for 105 Rh+ children with newly diagnosed immune thrombocytopenic purpura and a platelet count 20,000/μ L (P = 0.03). By day 7, hemoglobin concentrations decreased by 1.6 g/dL, 2 g/dL, and 0.3 g/dL in the anti- D50, anti- D75, and IVIg groups, respectively. Headache, fever, or chills occurred least often in the anti- D50 group. Conclusions: A single 75μ g/kg dose of Anti- D raised the platelet count in children with newly diagnosed immune thrombocytopenic purpura more rapidly than standard- dose anti- D and as effectively as IVIg, with an acceptable safety profile.
展开▼
